Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

• Status: Completed
• Trial end date: 2017-03-23

Summary

The goal of this clinical research study is to learn the most tolerable dose of Nexavarâ (sorafenib) when given in combination with Mobozilâ (plerixafor) and Neupogenâ (filgrastim) to patients with AML. The safety of this combination will also be studied.

Funding Source - FDA OOPD

• Phase: Phase 1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: Amgen; Bayer; Genzyme, a Sanofi Company; Georgia Institute of Technology; National Cancer Institute (NCI); Onyx Pharmaceuticals
• Treatments: JM 3100; Lenograstim; Niacinamide; Plerixafor; Sargramostim; Sorafenib